Hazard Identification and Risk Assessment for Biologics Targeting the Immune System

REFERENCES

• Attia P., Phan G. Q., Maker A. V., Robinson M. R., Quezado M. M., Yang J. C., Sherry R. M., Topalian S. L., Kammula U. S., Royal R. E., Restifo N. P., Haworth L. R., Levy C., Mavroukakis S. A., Nichol G., Yellin M. J., Rosenberg S. A. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 2005; 23: 6043–6053
   PubMed Web of Science ®Google Scholar
• Blansfield J. A., Beck K. E., Tran K., Yang J. C., Hughes M. S., Kammula U. S., Royal R. E., Topalian S. L., Haworth L. R., Levy C., Rosenberg S. A., Sherry R. M. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J. Immunother. 2005; 28: 593–598
   PubMed Web of Science ®Google Scholar
• Chiron. 2000, http://proleukin.com/info/prescribing_info.aspx Approved label for Proleukin®
   Google Scholar
• Clarke J., Leach W., Pippig S., Joshi A., Wu B., House R., Beyer J. Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody. Regul. Toxicol. Pharmacol. 2004; 40: 219–226
   PubMed Web of Science ®Google Scholar
• 2006, http://www.gpoaccess.gov/cfr/index.html Code of Federal Regulations CFR
   Google Scholar
• De Gagne J., Rouleau N., Cristiano N., Kirk S. A., LeSauteur L. Validation of a T-cell dependent antibody response in cynomolgus monkeys (Indonesian origin) using keyhole limpet hemocynanin. The Toxicologist/Toxicol. Sci. 2006; 90(S1)356
   Google Scholar
• Germolec D. R., Kashon M., Nyska A., Kuper C. F., Portier C., Kommineni C., Johnson K. A., Luster M. I. The accuracy of extended histopathology to detect immunotoxic chemicals. Toxicol. Sci. 2004; 82: 504–514
   PubMed Web of Science ®Google Scholar
• Glennie M. J., Johnson P. W. M. Clinical trials of antibody therapy. Immunol. Today 2000; 21: 403–410
   PubMedGoogle Scholar
• Gogas H., Ioannovich J., Dafni U., Stavropoulou-Giokas C., Frangia K., Tsoutsos D., Panagiotou P., Polyzos A., Papadopoulos O., Stratigos A., Markopoulos C., Bafaloukos D., Pectasides D., Fountzilas G., Kirkwood J. Prognostic significance of autoimmunity during treatment of melanoma with interferon. New Engl. J. Med. 2006; 354: 709–718
   PubMed Web of Science ®Google Scholar
• Green J. D., Black L. E. Status of preclinical safety assessment for immunomodulatory biopharmaceuticals. Human Exp. Toxicol. 2000; 19: 208–212
   PubMed Web of Science ®Google Scholar
• Greenlee J. E. Progressive multifocal leucoencephalopathy in the era of natalizumab: A review and discussion of the implications. Int. MS J. 2006; 13: 100–107
   PubMedGoogle Scholar
• Haley P., Perry R., Ennulat D., Frame S., Johnson C., Lapointe J. M., Nyska A., Snyder P. W., Walker D., Walter G. STP position paper: Best practice guideline for the routine pathology evaluation of the immune system. Toxicol. Pathol. 2005; 33: 404–407
   PubMed Web of Science ®Google Scholar
• Hall R. L. Principles of clinical pathology for toxicology studies. Principles and Methods of Toxicology, Fourth edition, A. W. Hayes. Taylor and Francis, Philadephia 2001; 1001–1038
   Google Scholar
• ICH. International Conference on Harmonisation. 1997, http://www.ich.org/cache/compo/276-254-1.html Preclinical safety evaluation of biotechnology-derived pharmaceuticals
   Google Scholar
• ICH. International Conference on Harmonisation. 2006, http://www.ich.org/cache/compo/276-254-1.html Immunotoxicity studies for human pharmaceuticals
   Google Scholar
• Klingbeil C., Hsu D. H. Pharmacology and safety assessment of humanized monoclonal antibodies for therapeutic use. Toxicol. Pathol. 1999; 27: 1–3
   Google Scholar
• Koon H., Atkins M. Autoimmunity and immunotherapy for cancer. New Engl. J. Med. 2006; 354: 758–760
   PubMed Web of Science ®Google Scholar
• Kuper C. F., Harleman J. H., Richter-Reichelm H. B., Vos J. G. Histopathologic approaches to detect changes indicative of immunotoxicity. Toxicol. Pathol. 2000; 28: 454–466
   PubMed Web of Science ®Google Scholar
• Lappin P. B., Black L. E. Immune modulator studies in primates: The utility of flow cytometry and immunohistochemistry in the identification and characterization of immunotoxicity. Toxicol. Pathol. 2003; 31(S1)111–118
   PubMedGoogle Scholar
• Mathieu M. The biological IND review process. Biologics Development a Regulatory Overview, Third Edition. PAREXEL International Corporation, Waltham, MA 2004; 53–77
   Google Scholar
• Mathieu M., Whisenand T. D., Spaulding A., Kane K. The biological license application. Biologics Development a Regulatory Overview, Third Edition. PAREXEL International Corporation, Waltham, MA 2004; 133–169
   Google Scholar
• Novak J. M., Whisenand T. D. The biological IND. Biologics Development a Regulatory Overview, Third Edition. PAREXEL International Corporation, Waltham, MA 2004; 25–51
   Google Scholar
• Rechetnik E., Satterwhite C. M., Black L. E., Lappin P. B. Optimization of an in vitro natural killer (NK) cell assay in cynomolgus monkeys. The Toxicologist/Tox. Sci. 2006; 90(S1)357
   Google Scholar
• Satterwhite C. M., Brodmerkel C. M., Vaddi K., Black L. E., Lappin P. B. A validation study of an in vivo delayed-type hypersensitivity (DTH) model in rhesus monkeys. The Toxicologist/Tox. Sci. 2006; 90(S1)356
   Google Scholar
• Serabian M. A., Pilaro A. M. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond. Toxicol. Pathol. 1999; 27: 27–31
   PubMed Web of Science ®Google Scholar
• Suntharalingam G., Perry M. R., Ward S., Brett S. J., Castello-Cortes A., Brunner M. D., Panoskaltsis N. Cytokine storm in a Phase 1 trial of anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 2006; 355: 1–11
   PubMed Web of Science ®Google Scholar
• US FDA. United States Food and Drug Administration. 2002, http://www.fda.gov/cder/guidance/index.htm#Pharmacology/Toxicology Guidance for Industry, Immunotoxicology evaluation of investigational new drugs
   Google Scholar
• US FDA. United States Food and Drug Administration. 2003, http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory Label information for Amevive
   Google Scholar
• US FDA. United States Food and Drug Administration. 2005, http://www.fda.gov/cder/guidance/index.htm#Pharmacology/Toxicology Guidance for Industry, Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers
   Google Scholar
• US FDA. United States Food and Drug Administration. 2006a, http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory Drugs@ FDA. Label information for Tysabri®
   Google Scholar
• US FDA. United States Food and Drug Administration. 2006b, http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory Drugs@ FDA. Label information for Remicade®
   Google Scholar
• US FDA. United States Food and Drug Administration. 2006c, http://www.accessdata.fda.gov/scripts/cder/drugs-atfda/index.cfm?fuseaction=Search.Label_ApprovalHistory Drugs@FDA. Review for Tysabri®
   Google Scholar
• US FDA. United States Food and Drug Administration. 2006d, http://www.fda.gov/cder/drug/infopage/natalizumab/default.htm Drugs @ FDA. Other important information from FDA
   Google Scholar
• Vugmeyster Y., Beyer J., Howell K., Combs D., Fielder P., Yang J., Qureshi F., Sandlund B., Kawaguchi L., Dummer W., Lowman H., McKeever K. Depletion of B-cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J. Immunother. 2005; 28: 212–219
   PubMed Web of Science ®Google Scholar
• Wilson N. H., Hardisty J. F., Hayes J. R. Short-term, subchronic, and chronic toxicology studies. Principles and Methods of Toxicology, Fourth edition, A. W. Hayes. Taylor and Francis, Philadephia 2001; 917–958
   Google Scholar